Skip to Content
|  |
|--|

| HomeWhat is Buprenorphine?Buprenorphine ProductsDATA Physician LocatorDATA 2000FAQsLinksEn EspañolPhysician Waiver QualificationsWaiver Notification FormOngoing Web-based  TrainingsWaived Physician WebBoardUpdate Physician Contact InformationModel State Medical Board PolicyBuprenorphine SummitsArticlesSAMHSA ReportsOther Gov't ReportsTo check on a physician's waivered status, please call the Buprenorphine Information Center at 1.866.287.2728.Nurses Guide to BuprenorphineOnline Buprenorphine Course for Counselors |  |   | For information about waiver status, DATA 2000 verifications, and questions about Buprenorphine, please call 1.866.287.2728 (1.866.BUP.CSAT)or email us at[email protected].
Number of DATA Certified Physicians: 
Click here to view a current list of Physicians Certified to Prescribe Buprenorphine by State and Year or here to download an Excel file of the same. This list is updated daily.The Drug Addiction Treatment Act of 2000 (DATA 2000)The Drug Addiction Treatment Act of 2000(DATA 2000) expands the clinical context of medication-assisted opioidaddiction treatment by allowing qualified physicians to dispense or prescribe specifically approved Schedule III, IV, and V narcotic medications for the treatment of opioid addiction in treatment settings other than the traditional Opioid Treatment Program (i.e., methadone clinic). In addition, DATA 2000 reduces the regulatory burden on physicians who choose to practice opioid addiction therapy by permitting qualified physicians to apply for and receive waivers of the special registration requirements defined in the ControlledSubstances Act. moreSAMHSA releases revised Federal Guidelines for Opioid Treatment ProgramsThe revised Federal Guidelines for Opioid Treatment Programs, published by the Substance Abuse and Mental Health Services Administration (SAMHSA), are now available.  Like the 2007 guidelines, the new guidelines conform to Title 42 of the Code of Federal Regulations Part 8.12.  SAMHSA periodically revises the guidelines to reflect best practices based on current evidence and changes in health care delivery.  To view press release click here. To obtain a copy of the revised guidelines use the following link http://store.samhsa.gov/product/PEP15-FEDGUIDEOTP. (Posted 3/31/15)The Substance Abuse and Mental Health Services Administration (SAMHSA) has partnered with the National Institute on Drug Abuse (NIDA)The Substance Abuse and Mental Health Services Administration (SAMHSA) has partnered with the National Institute on Drug Abuse (NIDA) to provide guidance for the use of medication assisted treatment (MAT) with extended-release injectable naltrexone for the treatment of an opioid use disorder. Click   here for further details.Risks of Marijuana usage and opioid addiction treatment medicationsMarijuana is the most commonly used illicit substance in the United States. This letter provides information about potential risks associated with marijuana use in patients being treated for opioid use disorders with medication assisted treatments such as methadone, buprenorphine, and naltrexone.  Continue reading...A document of great interest to physicians providing care for patients with addiction"Standards of Care: for the Addiction Specialist Physician" Fentanyl-Laced Heroin Linked To Dozens Of DeathsThe Substance Abuse and Mental Health Services Administration (SAMHSA) is alerting the treatment community and the general public that since the beginning of the year a marked increase in deaths reportedly linked to the use of heroin contaminated with the drug fentanyl has been noted. Fentanyl is a form of opioid and when used in combination with heroin can rapidly cause severe injury and even death. Continue reading...American Association for the Treatment of Opioid Dependence (AATOD) 2013 ConferenceThe City of Philadelphia, its Department of Behavioral Health Intellectual Disability Services, the State of Pennsylvania and its Department of Drug and Alcohol Programs are proud to host the American Association for the Treatment of Opioid Dependence (AATOD) 2013 Conference. Please visit the  AATOD 2013 Conference Page for additional information on the exciting opportunities in addiction treatment being offered at this conference.Get Your Copy of the Opioid Overdose ToolkitThe Opioid Overdose Toolkit educates first responders, physicians, patients, family members, and community members on ways to prevent opioid overdose. The toolkit also explains how to use a drug called naloxone to prevent overdose-related deaths. For additional information on the toolkit, please click here. To download your free copy, please visit the SAMHSA Store.CSAT Director Announces Upcoming Release of a New FDA Approved Buprenorphine ProductOn July 3, 2013, Orexo U.S. Inc. became the latest pharmaceutical company to add to the ever growing list of buprenorphine products. Orexo received approval from the U.S. Food and Drug Administration (FDA) for Zubsolv (buprenorphine and naloxone) sublingual tablets. Zubsolv is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Zubsolv is due to be released in September 2013. Click  here to read the letter in its entirety. A Recent Study Looking at the Treatment Outcomes Versus Type of Treatment Medication UsedThe authors of this study seek to explore differences in baseline clinical characteristics and opioid replacement therapy treatment outcomes by type or combined and route (injector or non-injector) of opioid use. Click  here to read the study in its entirety. CSAT Director Discusses Fentanyl AnaloguesMany of you will remember the period from 2005 through 2007 when illicit fentanyl-laced heroin caused a great number of overdose deaths. That was not the first time illicit fentanyl, also called fentanyl analogues, entered the drug market, and likely will not be the last. Recently, small clusters of overdoses and overdose fatalities in a variety of communities, mostly in the eastern United States, have raised alarm. Little is yet fully known about the situation but it appears fentanyl analogues are involved in at least some of the cases and may contaminate both heroin and cocaine. Click  here to read the letter in its entirety. Archived News What's New     Help with RSS Treatment Improvement ProtocolIncrease Patient Limits2005 SAMHSA Evaluation of the Impact of the DATA Waiver Program2006 Report On Diversion and Abuse of BuprenorphineDrug Enforcement Administraton (DEA)DATA Physician LocatorPhysicians' Clinical Support System-Buprenorphine
 The Substance Abuse and Mental Health Services Administration (SAMHSA) has partnered with the National Institute on Drug Abuse (NIDA) to provide guidance for the use of medication assisted treatment (MAT) with extended-release injectable naltrexone for the treatment of an opioid use disorderThe Affordable Care Act (ACA) in conjunction with the Mental Health Parity and Addiction Act (MHPAEA) OF 2008 has already provided an opportunity...CSAT Director Informs Physicians of Increase in Patient LimitsCSAT Director Notifies Physicians of a New Feature to the SAMHSA Buprenorphine Physician and Treatment Program LocatorCSAT Director Advises Physicians of Concerns Regarding BuprenorphineCSAT Director Encouraging Physicians to Sign-Up for the Buprenorphine Physician and Treatment Program Locator Home | Accessibility | Privacy | Disclaimer | SAMHSADepartment of Health & Human Services | USA.gov
* Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program.     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|